Developer docs
API playgroundTry for free, no card

Search company profiles

OncoHost

Full company profile

uuid0000mtz

Namestring
OncoHost
Legal namestring
OncoHost, Inc.
Websiteurl
oncohost.com
Company typeenum
Private
Founded yearint
2017
Descriptiontext

OncoHost is a clinical-stage precision oncology company founded in 2017 in Binyamina, Israel, that develops AI-powered plasma proteomics diagnostics to predict cancer patient response to immunotherapy. The company's flagship PROphet® platform uses machine learning algorithms trained on data from over 1,700 patients across 40+ clinical trial sites to analyze more than 7,000 circulating proteins per blood sample, generating a personalized PROphet Score (0-10) that predicts clinical benefit from PD-1/PD-L1 inhibitor therapy. The underlying proteomic measurement relies on a licensed SomaScan® assay (from SomaLogic) utilizing Slow-Off-Rate Modified Aptamers (SOMAmers), with proprietary serum-plasma proteomic bridging methodology enabling integration of heterogeneous datasets across studies.

The commercial product portfolio currently centers on PROphetNSCLC®, launched in the U.S. in February 2023 for first-line treatment decisions in metastatic non-small cell lung cancer, with PROphetRCC™ available for renal cell carcinoma and NeutroFlow (a rapid point-of-care test) in development under a €2.5 million EIC Transition grant. Revenue is generated via transaction-fee diagnostic testing services, with OncoHost billing patient insurance directly through its CLIA-certified, CAP-accredited laboratory in Cary, North Carolina, and offering a multi-channel ordering infrastructure (online physician portal, fax-based TRF, mobile phlebotomy) supported by Regional Sales Directors.

Go-to-market is enterprise field sales targeting oncologists and cancer treatment centers — the platform has been adopted across approximately 200 U.S. cancer centers, with reported clinical impact that 93% of oncologists adjust treatment recommendations based on PROphet results. The company serves two principal customer segments: oncologists/cancer centers (primary, for clinical decision-making) and pharmaceutical companies (secondary, for clinical trial patient stratification and companion diagnostic applications, evidenced by partnerships with Henlius, Roswell Park, and others). Operating geographies span North America (U.S. commercial), the Middle East (Israeli R&D headquarters), and Europe (UK NHS clinical trial sites, EU collaborations).

Short descriptiontext

OncoHost is a clinical-stage precision oncology company that uses AI-driven plasma proteomics to predict cancer patient response to immunotherapy. Its PROphet® platform analyzes over 7,000 circulating proteins to guide first-line treatment decisions for oncologists across U.S. cancer centers.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBinyamina, Israel
HQ citystring
Binyamina
HQ countrystring
Israel
HQ regionstring
Middle East
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
precision oncology diagnostics, plasma proteomics testing, immunotherapy response prediction, clinical biomarker development, cancer diagnostic solutions
Industry3 codes
PRIMARYHLAAAMAC
Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAIALAE
Clinical Development (Phase I–III Trial Design & Execution)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAGACAE
Clinical Trial Site Operations & Study Coordination
NAICS code3 codes
  • Medical Laboratories621511
  • In-Vitro Diagnostic Substance Manufacturing325413
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • In Vitro & In Vivo Diagnostic Substances2835
  • Services-Medical Laboratories8071
Product category
Precision Oncology Diagnostics
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Laboratory Diagnostic Testing Services
TypeTransaction Fee
Description

OncoHost generates revenue through its CLIA-certified laboratory providing the PROphetNSCLC test. The company bills patient insurance directly, with financial assistance available for qualifying patients. Patients may receive Explanation of Benefits from insurance but are only responsible for co-insurance based on plan-allowed amounts without balance billing.

Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain
Pricing details1 tier
1Insurance-billed diagnostic test
ModelTransaction based/ take rateBilling cadencePay-as-you-go
Notes

OncoHost bills patient's insurance company once the report has been completed. Patients may receive EOB notice but this is not a bill. Patients only responsible for co-insurance based on plan-allowed amount.

GTM typeB2B
B2B
Offering typeServices
Services
Brand1 record
1PROphet®
Description

AI-powered plasma proteomics platform that predicts patient response to immunotherapy and generates personalized PROphet® scores for treatment decision support.

oncohost.com
Core offering1 text field

OncoHost develops and commercializes the PROphet® platform, an AI-powered plasma proteomics diagnostic that uses the SomaScan assay (measuring ~7,000 circulating proteins per sample) to generate a personalized PROphet® Score predicting clinical benefit from PD-1/PD-L1 inhibitor immunotherapy. The commercially launched PROphetNSCLC® test supports first-line treatment decisions for metastatic non-small cell lung cancer, processed through the company's CLIA-certified laboratory in Cary, North Carolina.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 93% of oncologists adjust treatment recommendations with PROphetNSCLC test
+2 more records
Product overview1 text field

OncoHost offers a precision oncology platform centered on the PROphet® AI-powered plasma proteomics system. The core PROphet® Platform analyzes over 7,000 circulating proteins per patient using machine learning to generate predictive scores for immunotherapy response. Two diagnostic tests have been commercialized: PROphetNSCLC® for non-small cell lung cancer and PROphetRCC™ for renal cell carcinoma. A third test, NeutroFlow, is in development as a rapid point-of-care solution. The platform integrates SomaScan® assay technology (licensed from SomaLogic) for high-throughput proteomic profiling of blood samples prior to treatment initiation.

Product and service3 records
1PROphetNSCLC® Test
CategoryDiagnostic test
Description

Blood-based diagnostic test intended for managing non-resectable stage III and IV non-small cell lung cancer (NSCLC) patients treated with first-line anti-PD-1/PD-L1-based therapy as a single agent or in combination with chemotherapy. Provides a personalized PROphet® Score between 0-10 with POSITIVE (5-10) or NEGATIVE (0-5) classification.

2PROphetRCC™ Test
CategoryDiagnostic test
Description

Treatment decision tool for newly diagnosed stage IV Renal Cell Carcinoma (RCC) patients being considered for treatment with immune checkpoint inhibitors (ICIs) and/or tyrosine kinase inhibitors (TKIs) in the first-line setting.

3PROphet® Platform
CategoryCore technology platform
Description

AI-powered plasma proteomics platform that uses machine learning to analyze over 7,000 circulating proteins per patient and generate a personalized PROphet® Score predicting clinical benefit from immunotherapy (PD-1/PD-L1 inhibitors). Underlies the company's commercial diagnostic tests.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership13 partners
Strategic tierKeyTypeStrategic or Co-development PartnerAnnounced on2026-02-18
Description

Multi-institutional collaboration on landmark JPBA study demonstrating serum-plasma proteomic bridging methodology. NCI researchers collaborated with OncoHost scientific team on high-throughput proteomic profiling research.

Strategic tierKeyTypeStrategic or Co-development PartnerAnnounced on2026-02-18
Description

Multi-institutional collaboration on JPBA study developing computational framework for integrating serum and plasma proteomic datasets for biomarker studies.

Strategic tierKeyTypeStrategic or Co-development PartnerAnnounced on2026-02-18
Description

Collaborated with OncoHost on serum-plasma proteomic bridging study published in Journal of Pharmaceutical and Biomedical Analysis. Previously partnered on lung cancer biomarkers research (December 2021).

4ions.bio
Strategic tierSupportingTypeStrategic or Co-development PartnerAnnounced on2026-02-18
Description

Biomarker development company collaborating with OncoHost and other institutions on serum-plasma proteomic bridging research published in JPBA.

oncohost.com
Strategic tierKeyTypeStrategic or Co-development PartnerAnnounced on2025-02-26
Description

Partnership to advance predictive markers for immune-related adverse events (irAEs). Research collaboration focusing on identifying biomarkers that can predict which patients will experience adverse events from immunotherapy.

6Baylor Scott & White Research Institute
Strategic tierSupportingTypeStrategic or Co-development PartnerAnnounced on2024-01-10
Description

Collaborative research study to analyze resistance mechanisms in lung cancer patients, combining institutional expertise with OncoHost's proteomic analysis capabilities.

oncohost.com
Strategic tierSupportingTypeStrategic or Co-development PartnerAnnounced on2024-01-10
Description

Partnered with Baylor Scott & White Research Institute and OncoHost to investigate resistance mechanisms in lung cancer using advanced genomic and proteomic approaches.

8Henlius
Strategic tierKeyTypeStrategic or Co-development PartnerAnnounced on2023-10-03
Description

OncoHost's PROphet platform supporting Henlius US-based Phase III trial for patients with extensive-stage small cell lung cancer (SCLC), providing biomarker analysis for patient stratification.

oncohost.com
Strategic tierSupportingTypeStrategic or Co-development PartnerAnnounced on2023-05-04
Description

Collaboration to predict cancer patient response to anti-PD-1 treatment using IcAR Biosensing Technology, combining BGN's biosensing expertise with OncoHost's proteomic platform.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2022-06-13
Description

SomaLogic granted OncoHost a license to use the SomaScan assay platform for the development of precision cancer diagnostics. The SomaScan platform uses Slow-Off-Rate Modified Aptamers (SOMAmers) to measure approximately 7,000 proteins per sample.

Strategic tierKeyTypeStrategic or Co-development PartnerAnnounced on2022-04-05
Description

Clinical trial collaboration to analyze immunotherapy resistance in cancer patients, leveraging Roswell Park's clinical expertise and patient population.

Strategic tierKeyTypeStrategic or Co-development PartnerAnnounced on2021-06-16
Description

NHS opened eight UK clinical trial sites to assess cancer patient response to immunotherapy in collaboration with OncoHost, enabling international clinical validation.

Strategic tierSupportingTypeStrategic or Co-development PartnerAnnounced on2020-01-21
Description

Joint grant partnership awarded $1 million from BIRD Foundation to advance precision oncology for patients receiving immunotherapy, combining proteomic analysis with array technologies.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Biodesix develops blood-based diagnostic tests for lung cancer (e.g., Nodify Lung) to guide treatment decisions, directly competing with PROphetNSCLC in the lung cancer diagnostic testing market.

TypeBroad incumbent
Description

Guardant Health is an established liquid biopsy company offering comprehensive genomic profiling tests for advanced cancer patients, broadly competing in oncology diagnostics where OncoHost's PROphet also operates.

TypeBroad incumbent
Description

Foundation Medicine is a leading molecular diagnostics company providing comprehensive genomic profiling (FoundationOne CDx), serving overlapping oncologist and biopharma customers seeking precision oncology decision support.

TypeDirect peer
Description

Caris offers molecular profiling (MI Profile) and AI-driven precision oncology solutions that compete with PROphet for oncologist adoption in therapy selection for advanced cancer patients.

5Tempus AI
TypeBroad incumbent
Description

Tempus AI combines multimodal data (genomics, imaging, clinical) with AI for precision oncology, competing with OncoHost in the AI-driven oncology decision-support space and serving similar oncologist and biopharma customers.

TypeDirect peer
Description

Personalis provides ultra-sensitive liquid biopsy tests for tumor profiling and MRD, overlapping with OncoHost's blood-based approach to inform immunotherapy and oncology treatment decisions.

TypeDirect peer
Description

Natera offers Signatera (tumor-informed MRD) and other oncology blood tests, competing in the blood-based oncology diagnostics market and serving oncologists making treatment decisions.

TypeBroad incumbent
Description

NeoGenomics is an established oncology reference laboratory providing a broad menu of oncology testing services to community hospitals and oncologists, broadly competing with OncoHost's CLIA-certified lab offering.

TypeEmerging player
Description

Adaptive Biotechnologies offers immune profiling (clonoSEQ, T-Detect) and is expanding into immune-related oncology applications, with partial overlap to OncoHost's host-response and immunotherapy biomarker focus.

TypeEmerging player
Description

Olink provides high-throughput proteomics platforms (Olink Explore) used in biomarker discovery and translational research, serving adjacent proteomics customers and enabling similar cancer biomarker work to OncoHost's SomaScan-based pipeline.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors8 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

OncoHost

Precision Oncology Diagnosticsoncohost.com

OncoHost is a clinical-stage precision oncology company that uses AI-driven plasma proteomics to predict cancer patient response to immunotherapy. Its PROphet® platform analyzes over 7,000 circulating proteins to guide first-line treatment decisions for oncologists across U.S. cancer centers.

What OncoHost does

OncoHost is a clinical-stage precision oncology company founded in 2017 in Binyamina, Israel, that develops AI-powered plasma proteomics diagnostics to predict cancer patient response to immunotherapy. The company's flagship PROphet® platform uses machine learning algorithms trained on data from over 1,700 patients across 40+ clinical trial sites to analyze more than 7,000 circulating proteins per blood sample, generating a personalized PROphet Score (0-10) that predicts clinical benefit from PD-1/PD-L1 inhibitor therapy. The underlying proteomic measurement relies on a licensed SomaScan® assay (from SomaLogic) utilizing Slow-Off-Rate Modified Aptamers (SOMAmers), with proprietary serum-plasma proteomic bridging methodology enabling integration of heterogeneous datasets across studies.

The commercial product portfolio currently centers on PROphetNSCLC®, launched in the U.S. in February 2023 for first-line treatment decisions in metastatic non-small cell lung cancer, with PROphetRCC™ available for renal cell carcinoma and NeutroFlow (a rapid point-of-care test) in development under a €2.5 million EIC Transition grant. Revenue is generated via transaction-fee diagnostic testing services, with OncoHost billing patient insurance directly through its CLIA-certified, CAP-accredited laboratory in Cary, North Carolina, and offering a multi-channel ordering infrastructure (online physician portal, fax-based TRF, mobile phlebotomy) supported by Regional Sales Directors.

Go-to-market is enterprise field sales targeting oncologists and cancer treatment centers — the platform has been adopted across approximately 200 U.S. cancer centers, with reported clinical impact that 93% of oncologists adjust treatment recommendations based on PROphet results. The company serves two principal customer segments: oncologists/cancer centers (primary, for clinical decision-making) and pharmaceutical companies (secondary, for clinical trial patient stratification and companion diagnostic applications, evidenced by partnerships with Henlius, Roswell Park, and others). Operating geographies span North America (U.S. commercial), the Middle East (Israeli R&D headquarters), and Europe (UK NHS clinical trial sites, EU collaborations).

OncoHost firmographics

Firmographics
Name
OncoHost
Legal name
OncoHost, Inc.
Website
https://oncohost.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
11–50 employees
Short description
OncoHost is a clinical-stage precision oncology company that uses AI-driven plasma proteomics to predict cancer patient response to immunotherapy. Its PROphet® platform analyzes over 7,000 circulating proteins to guide first-line treatment decisions for oncologists across U.S. cancer centers.
Ownership category
akta.pro rank

OncoHost industry classification

Industry
Product category
Precision Oncology Diagnostics
NAICS
Medical Laboratories (621511), In-Vitro Diagnostic Substance Manufacturing (325413), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHLAAAMAC
Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAIALAE
Clinical Development (Phase I–III Trial Design & Execution)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAGACAE
Clinical Trial Site Operations & Study Coordination

Keywords

  • Precision oncology diagnostics
  • Plasma proteomics testing
  • Immunotherapy response prediction
  • Clinical biomarker development
  • Cancer diagnostic solutions

Where OncoHost is headquartered

Location

Headquarters

HQ city
Binyamina
HQ country
Israel
HQ region
Middle East

Offices2 records

Markets served

OncoHost business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. Laboratory Diagnostic Testing Services: OncoHost generates revenue through its CLIA-certified laboratory providing the PROphetNSCLC test. The company bills patient insurance directly, with financial assistance available for qualifying patients. Patients may receive Explanation of Benefits from insurance but are only responsible for co-insurance based on plan-allowed amounts without balance billing.

Pricing tiers

ModelBillingPrice
Transaction based/ take ratePay-as-you-goInsurance-billed diagnostic test

Go-to-market motion1 record

Distribution channels4 records

Marketing channels5 records

OncoHost product offering

Product offering

Core offering

OncoHost develops and commercializes the PROphet® platform, an AI-powered plasma proteomics diagnostic that uses the SomaScan assay (measuring ~7,000 circulating proteins per sample) to generate a personalized PROphet® Score predicting clinical benefit from PD-1/PD-L1 inhibitor immunotherapy. The commercially launched PROphetNSCLC® test supports first-line treatment decisions for metastatic non-small cell lung cancer, processed through the company's CLIA-certified laboratory in Cary, North Carolina.

Product overview

OncoHost offers a precision oncology platform centered on the PROphet® AI-powered plasma proteomics system. The core PROphet® Platform analyzes over 7,000 circulating proteins per patient using machine learning to generate predictive scores for immunotherapy response. Two diagnostic tests have been commercialized: PROphetNSCLC® for non-small cell lung cancer and PROphetRCC™ for renal cell carcinoma. A third test, NeutroFlow, is in development as a rapid point-of-care solution. The platform integrates SomaScan® assay technology (licensed from SomaLogic) for high-throughput proteomic profiling of blood samples prior to treatment initiation.

Differentiator

Problem solved

Functional benefit

Brands

  • PROphet®: AI-powered plasma proteomics platform that predicts patient response to immunotherapy and generates personalized PROphet® scores for treatment decision support.

Products and services

  • PROphetNSCLC® Test Blood-based diagnostic test intended for managing non-resectable stage III and IV non-small cell lung cancer (NSCLC) patients treated with first-line anti-PD-1/PD-L1-based therapy as a single agent or in combination with chemotherapy. Provides a personalized PROphet® Score between 0-10 with POSITIVE (5-10) or NEGATIVE (0-5) classification.
  • PROphetRCC™ Test Treatment decision tool for newly diagnosed stage IV Renal Cell Carcinoma (RCC) patients being considered for treatment with immune checkpoint inhibitors (ICIs) and/or tyrosine kinase inhibitors (TKIs) in the first-line setting.
  • PROphet® Platform AI-powered plasma proteomics platform that uses machine learning to analyze over 7,000 circulating proteins per patient and generate a personalized PROphet® Score predicting clinical benefit from immunotherapy (PD-1/PD-L1 inhibitors). Underlies the company's commercial diagnostic tests.

Quantifiable outcome

  • 93% of oncologists adjust treatment recommendations with PROphetNSCLC test
  • +2 more outcomes

Companies that use OncoHost

Customer profile

Named customers2 records

Segments2 records

Ideal customer profiles2 records

OncoHost technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature4 records

OncoHost partnerships and signals

Strategic signal

Partnerships

13 partnerships are on record, tiered key, supporting and core.

  • National Cancer Institute (NCI)keyStrategic or Co-development Partner · 18 February 2026Multi-institutional collaboration on landmark JPBA study demonstrating serum-plasma proteomic bridging methodology. NCI researchers collaborated with OncoHost scientific team on high-throughput proteomic profiling research.
  • Yale School of MedicinekeyStrategic or Co-development Partner · 18 February 2026Multi-institutional collaboration on JPBA study developing computational framework for integrating serum and plasma proteomic datasets for biomarker studies.
  • Heidelberg University HospitalkeyStrategic or Co-development Partner · 18 February 2026Collaborated with OncoHost on serum-plasma proteomic bridging study published in Journal of Pharmaceutical and Biomedical Analysis. Previously partnered on lung cancer biomarkers research (December 2021).
  • ions.biosupportingStrategic or Co-development Partner · 18 February 2026Biomarker development company collaborating with OncoHost and other institutions on serum-plasma proteomic bridging research published in JPBA.
  • Gustave Roussy Cancer InstitutekeyStrategic or Co-development Partner · 26 February 2025Partnership to advance predictive markers for immune-related adverse events (irAEs). Research collaboration focusing on identifying biomarkers that can predict which patients will experience adverse events from immunotherapy.
  • Baylor Scott & White Research InstitutesupportingStrategic or Co-development Partner · 10 January 2024Collaborative research study to analyze resistance mechanisms in lung cancer patients, combining institutional expertise with OncoHost's proteomic analysis capabilities.
  • TGen (Translational Genomics Research Institute)supportingStrategic or Co-development Partner · 10 January 2024Partnered with Baylor Scott & White Research Institute and OncoHost to investigate resistance mechanisms in lung cancer using advanced genomic and proteomic approaches.
  • HenliuskeyStrategic or Co-development Partner · 3 October 2023OncoHost's PROphet platform supporting Henlius US-based Phase III trial for patients with extensive-stage small cell lung cancer (SCLC), providing biomarker analysis for patient stratification.
  • BGN TechnologiessupportingStrategic or Co-development Partner · 4 May 2023Collaboration to predict cancer patient response to anti-PD-1 treatment using IcAR Biosensing Technology, combining BGN's biosensing expertise with OncoHost's proteomic platform.
  • SomaLogic Inc.coreTechnology or Integration · 13 June 2022SomaLogic granted OncoHost a license to use the SomaScan assay platform for the development of precision cancer diagnostics. The SomaScan platform uses Slow-Off-Rate Modified Aptamers (SOMAmers) to measure approximately 7,000 proteins per sample.
  • Roswell Park Comprehensive Cancer CenterkeyStrategic or Co-development Partner · 5 April 2022Clinical trial collaboration to analyze immunotherapy resistance in cancer patients, leveraging Roswell Park's clinical expertise and patient population.
  • NHS (UK National Health Service)keyStrategic or Co-development Partner · 16 June 2021NHS opened eight UK clinical trial sites to assess cancer patient response to immunotherapy in collaboration with OncoHost, enabling international clinical validation.
  • RayBiotechsupportingStrategic or Co-development Partner · 21 January 2020Joint grant partnership awarded $1 million from BIRD Foundation to advance precision oncology for patients receiving immunotherapy, combining proteomic analysis with array technologies.

Scale indicators7 records

Recent moves8 records

Expansion highlights7 records

OncoHost competitors and assessment

Company assessment

Direct peers

  • Biodesix: Biodesix develops blood-based diagnostic tests for lung cancer (e.g., Nodify Lung) to guide treatment decisions, directly competing with PROphetNSCLC in the lung cancer diagnostic testing market.
  • Caris Life Sciences: Caris offers molecular profiling (MI Profile) and AI-driven precision oncology solutions that compete with PROphet for oncologist adoption in therapy selection for advanced cancer patients.
  • Personalis: Personalis provides ultra-sensitive liquid biopsy tests for tumor profiling and MRD, overlapping with OncoHost's blood-based approach to inform immunotherapy and oncology treatment decisions.
  • Natera: Natera offers Signatera (tumor-informed MRD) and other oncology blood tests, competing in the blood-based oncology diagnostics market and serving oncologists making treatment decisions.

Broad incumbents

  • Guardant Health: Guardant Health is an established liquid biopsy company offering comprehensive genomic profiling tests for advanced cancer patients, broadly competing in oncology diagnostics where OncoHost's PROphet also operates.
  • Foundation Medicine: Foundation Medicine is a leading molecular diagnostics company providing comprehensive genomic profiling (FoundationOne CDx), serving overlapping oncologist and biopharma customers seeking precision oncology decision support.
  • Tempus AI: Tempus AI combines multimodal data (genomics, imaging, clinical) with AI for precision oncology, competing with OncoHost in the AI-driven oncology decision-support space and serving similar oncologist and biopharma customers.
  • NeoGenomics: NeoGenomics is an established oncology reference laboratory providing a broad menu of oncology testing services to community hospitals and oncologists, broadly competing with OncoHost's CLIA-certified lab offering.

Emerging players

  • Adaptive Biotechnologies: Adaptive Biotechnologies offers immune profiling (clonoSEQ, T-Detect) and is expanding into immune-related oncology applications, with partial overlap to OncoHost's host-response and immunotherapy biomarker focus.
  • Olink: Olink provides high-throughput proteomics platforms (Olink Explore) used in biomarker discovery and translational research, serving adjacent proteomics customers and enabling similar cancer biomarker work to OncoHost's SomaScan-based pipeline.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

OncoHost social profiles

Digital presence

OncoHost compliance and trust

Trust signal

Compliance3 records

OncoHost financial estimates

Financial estimate

Revenue estimate

Valuation estimate

OncoHost leadership team

Management profile

Number of profiles

Profiles10 records

OncoHost subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

OncoHost funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

OncoHost M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about OncoHost

What does OncoHost do?

OncoHost develops and commercializes the PROphet® platform, an AI-powered plasma proteomics diagnostic that uses the SomaScan assay (measuring ~7,000 circulating proteins per sample) to generate a personalized PROphet® Score predicting clinical benefit from PD-1/PD-L1 inhibitor immunotherapy. The commercially launched PROphetNSCLC® test supports first-line treatment decisions for metastatic non-small cell lung cancer, processed through the company's CLIA-certified laboratory in Cary, North Carolina.

Is OncoHost a public or private company?

OncoHost is a private company. It is classified as venture growth investor backed and is currently operating.

When was OncoHost founded?

OncoHost was founded in 2017. It employs 11 to 50 people.

Where is OncoHost based?

OncoHost is headquartered in Binyamina, Israel, in the Middle East region.

How does OncoHost make money?

One revenue line is on record: laboratory Diagnostic Testing Services.

Who are OncoHost's main competitors?

Direct peers on record are Biodesix, Caris Life Sciences, Personalis and Natera. Broad incumbents are Guardant Health, Foundation Medicine, Tempus AI and NeoGenomics. Emerging players are Adaptive Biotechnologies and Olink.

Does OncoHost have an API?

No public API is recorded for OncoHost.

What industry is OncoHost in?

OncoHost's product category is Precision Oncology Diagnostics. Its primary akta.pro industry code is HLAAAMAC, Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays), with a secondary code of HLAIALAE, Clinical Development (Phase I–III Trial Design & Execution). Its NAICS code is 621511 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireOncoHost to Present New Research on Early Detection of Immunotherapy Resistance Using Plasma Proteomics at ISLB 2026OncoHost will present new research at ISLB 2026 on a 22-protein plasma signature for monitoring immunotherapy response in advanced NSCLC. The study of 440 samples from 109 patients detected acquired resistance a median of 170 days before radiologic progression. Further prospective validation is required.PR NewswireOncoHost to Present New Research on Early Detection of Immunotherapy Resistance Using Plasma Proteomics at ISLB 2026OncoHost will present new research at ISLB 2026 on a 22-protein plasma signature for monitoring immunotherapy response in advanced NSCLC. The study of 440 samples detected acquired resistance a median of 170 days before radiologic progression. Further prospective validation is required for clinical utility.PR NewswireOncoHost Presents New Research Revealing Biological Drivers of TKI Sensitivity in Metastatic Renal Cell Carcinoma at ESMO 2026OncoHost presented new research at ESMO 2026 linking plasma proteomics to TKI sensitivity in metastatic renal cell carcinoma. The model, developed with Dana-Farber, classified patients as TKI-Positive or TKI-Negative, with TKI-Positive patients showing significantly longer overall survival on ICI-TKI therapy (HR 0.14, p=0.003). The study identified angiogenesis and vascular remodeling pathways as key biological drivers.PR NewswireOncoHost to Present New PROphetNSCLC® Data at WCLC 2026 Demonstrating Predictive Performance Beyond Baseline SamplingOncoHost will present a poster at WCLC 2026 showing PROphetNSCLC maintains predictive performance after chemotherapy or immunotherapy. The study found over 73% of RAPs remained correlated, with 80% classification concordance after chemotherapy and 69% after one ICI cycle. The findings expand real-world clinical utility for patients without baseline samples.PR NewswireOncoHost to Present New Research on Proteomic Aging Biomarkers Outcomes at AACR 2026OncoHost announced its acceptance to present new research at the AACR Annual Meeting 2026 in San Diego, examining how proteomic aging biomarkers can predict immunotherapy outcomes across multiple cancer types. The study found that cancer patients exhibit significantly elevated biological age compared to healthy individuals, and patients with high immune age gap treated with immune checkpoint inhibitors had markedly shorter overall survival (median OS: 16.4 vs 31.8 months). The research highlights the potential of quantifying biological aging processes to improve patient stratification and treatment decision-making in precision oncology.PR NewswireOncoHost Wins 2026 Artificial Intelligence Excellence Award in Health CategoryOncoHost, an AI-driven precision oncology company, was named a winner in the 2026 Artificial Intelligence Excellence Awards in the health category by the Business Intelligence Group. The company was recognized for its PROphet® platform, a machine learning-based proteomics solution that predicts immunotherapy outcomes by analyzing over 7,000 proteins per patient. The platform has been adopted across approximately 200 U.S. cancer centers and is used by hundreds of oncologists for first-line treatment decisions in metastatic non-small cell lung cancer.PR NewswireOncoHost Publishes Landmark Study in JPBA Demonstrating Serum-Plasma Proteomic Bridging, Expanding Biomarker Research CapabilitiesOncoHost announced the publication of a study in the Journal of Pharmaceutical and Biomedical Analysis introducing a validated computational framework that harmonizes serum and plasma proteomic datasets, overcoming a long-standing analytical barrier that had limited direct data integration across specimen types. The study analyzed 7,289 proteins using the SomaScan platform on 177 matched serum-plasma sample pairs from cancer patients across three independent cohorts, finding a 91.6% statistically significant correlation between serum and plasma measurements. The research validated this bridging methodology using OncoHost's PROphet AI platform for predicting immunotherapy outcomes in non-small cell lung cancer patients, demonstrating that predictive models can be reliably extended across specimen types.PR NewswireOncoHost Wins 2026 BIG Innovation Award in Health Category; Named a Top 10 Innovator - Small BusinessOncoHost, a precision medicine technology company, has been named a winner of the 2026 BIG Innovation Awards in the Health category and selected as a Top 10 Innovator in the Small Business category by the Business Intelligence Group. The company was recognized for its PROphet® platform, an AI-driven plasma-proteomics solution that analyzes over 7,000 circulating proteins per patient to guide immunotherapy decision-making in metastatic non-small cell lung cancer. OncoHost is headquartered in Binyamina, Israel and Cary, North Carolina, with ongoing clinical trials involving over 40 sites and 1,700 patients worldwide.PR NewswireOncoHost Named Gold Winner in 2025 Merit Awards for Healthcare - Technology Solution of the YearOncoHost was named the Gold Winner for Technology Solution of the Year at the 2025 Merit Awards for Healthcare, recognizing its AI-powered PROphet® platform. The platform utilizes plasma proteomics to predict patient response to cancer therapy, with specific commercial offerings for non-small cell lung cancer and other tumor types underway. This award highlights the company's global momentum and clinical value in advancing precision oncology.OncohostOncoHost Named Top Precision Oncology Solution for 2025OncoHost was named the Top Precision Oncology Solution for 2025 by Life Sciences Review following a rigorous evaluation process involving industry stakeholders and an editorial board. The recognition highlights its flagship platform, PROphet®, which utilizes AI and proteomics to predict clinical benefits and resistance mechanisms in cancer treatment. This accolade serves as an endorsement of OncoHost's strategy to shift precision oncology focus toward the patient's full biological context.